Vaughan David Investments LLC IL Has $30.71 Million Position in Zoetis Inc. $ZTS

Vaughan David Investments LLC IL lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 209,846 shares of the company’s stock after acquiring an additional 6,325 shares during the period. Vaughan David Investments LLC IL’s holdings in Zoetis were worth $30,705,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Halbert Hargrove Global Advisors LLC raised its stake in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the period. REAP Financial Group LLC lifted its position in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares in the last quarter. NewSquare Capital LLC boosted its holdings in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. ORG Partners LLC boosted its position in shares of Zoetis by 56.8% in the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after acquiring an additional 84 shares during the period. Finally, Financial Consulate Inc. purchased a new position in Zoetis during the third quarter worth about $39,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Barclays initiated coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. KeyCorp began coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. UBS Group lowered their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Stifel Nicolaus dropped their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Finally, The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $160.18.

Zoetis Stock Performance

ZTS stock opened at $122.14 on Tuesday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $53.82 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 2.53 and a beta of 0.97. The stock’s 50 day simple moving average is $123.31 and its 200 day simple moving average is $139.11. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the previous year, the company earned $1.58 earnings per share. The firm’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.